SOTAC PHARMACEUTICALS
|
SOTAC PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 7.26 | 3.87 | 3.58 | 12.52 | -10.28 |
| CEPS(Rs) | 11.86 | 6.05 | 5.67 | 4.98 | 0.28 |
| DPS(Rs) | 0.10 | - | - | 2.00 | - |
| Book NAV/Share(Rs) | 48.19 | 40.96 | 12.41 | 28.79 | 10.84 |
| Tax Rate(%) | 16.59 | 9.70 | 41.78 | 38.68 | -15.02 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 14.06 | 8.01 | 9.44 | 8.44 | 2.98 |
| EBIT Margin(%) | 14.13 | 5.49 | 7.70 | 7.20 | -2.11 |
| Pre Tax Margin(%) | 11.47 | 3.82 | 5.07 | 6.42 | -4.21 |
| PAT Margin (%) | 9.56 | 3.45 | 2.95 | 3.94 | -4.84 |
| Cash Profit Margin (%) | 13.52 | 6.43 | 5.89 | 5.48 | 0.47 |
| Performance Ratios | |||||
| ROA(%) | 8.17 | 4.03 | 4.20 | 8.23 | -7.27 |
| ROE(%) | 18.83 | 12.96 | 27.53 | 63.16 | -85.23 |
| ROCE(%) | 16.40 | 10.22 | 21.50 | 31.31 | -5.71 |
| Asset Turnover(x) | 0.85 | 1.17 | 1.42 | 2.09 | 1.50 |
| Sales/Fixed Asset(x) | 1.79 | 2.65 | 3.34 | 4.12 | 2.39 |
| Working Capital/Sales(x) | 5.31 | 6.14 | 58.39 | -42.31 | -9.02 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.56 | 0.38 | 0.30 | 0.24 | 0.42 |
| Receivable days | 113.65 | 72.11 | 63.58 | 45.25 | 47.99 |
| Inventory Days | 72.01 | 55.63 | 44.84 | 25.51 | 26.72 |
| Payable days | 127.81 | 124.45 | 143.83 | 106.65 | 112.91 |
| Valuation Parameters | |||||
| PER(x) | 16.35 | 31.23 | - | - | - |
| PCE(x) | 10.01 | 20.02 | - | - | - |
| Price/Book(x) | 2.46 | 2.95 | - | - | - |
| Yield(%) | 0.08 | - | - | - | - |
| EV/Net Sales(x) | 1.79 | 1.49 | 0.26 | 0.13 | 0.39 |
| EV/Core EBITDA(x) | 9.89 | 17.63 | 2.66 | 1.51 | 12.26 |
| EV/EBIT(x) | 12.65 | 27.21 | 3.42 | 1.83 | -18.58 |
| EV/CE(x) | 1.79 | 2.21 | 0.49 | 0.27 | 0.55 |
| M Cap / Sales | 1.35 | 1.29 | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | -6.59 | 34.00 | 5.92 | 49.77 | 70.76 |
| Core EBITDA Growth(%) | 99.21 | 14.83 | 19.94 | 309.00 | -25.23 |
| EBIT Growth(%) | 140.28 | -4.46 | 13.37 | 610.65 | -249.43 |
| PAT Growth(%) | 159.14 | 56.57 | -20.58 | 221.70 | -2,803.31 |
| EPS Growth(%) | 87.48 | 8.32 | -71.42 | 221.70 | -2,803.31 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.82 | 0.55 | 2.21 | 1.12 | 6.87 |
| Current Ratio(x) | 1.35 | 1.39 | 1.03 | 0.94 | 0.76 |
| Quick Ratio(x) | 0.96 | 0.97 | 0.73 | 0.74 | 0.55 |
| Interest Cover(x) | 5.31 | 3.28 | 2.92 | 9.24 | -1.01 |
| Total Debt/Mcap(x) | 0.33 | 0.19 | - | - | - |
Compare Financial Ratios of peers of SOTAC PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SOTAC PHARMACEUTICALS | ₹137.0 Cr | -11.6% | -1.3% | 7.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹424,982.0 Cr | -0.7% | -0.5% | -3.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹172,878.0 Cr | 2.8% | 2.2% | 10.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹129,095.0 Cr | 1.5% | 3.4% | 12.4% | Stock Analytics | |
| CIPLA | ₹122,175.0 Cr | 0.8% | 0.1% | 3.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,154.0 Cr | 0.4% | 3.2% | 0.3% | Stock Analytics | |
SOTAC PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SOTAC PHARMACEUTICALS | -11.6% |
-1.3% |
7.9% |
| SENSEX | 0.4% |
-0.1% |
6.1% |
You may also like the below Video Courses
